ArcaScience

ArcaScience is the only AI-native Benefit-Risk Analysis (BRA) platform, built on 23 proprietary AI models, hybridizing LLMs and encoder-based infrastructures—a breakthrough that global pharma giants failed to achieve (Roche’s Voyager, Sanofi’s Darwin, Novartis’ Data42). Nearly a spin-off of INRIA, we deliver instant, AI-driven BRA at scale, where others rely on slow, manual consulting.

🚀 Key Achievements & Traction:
✅ $2M contract with the giant ICON  → 480 drugs evaluated for 200+ clients in a 60,000-drug market
✅ Trusted by top pharma & CROs → Clients include Sanofi, AstraZeneca, ICON, Vidal, MRT
✅ Validated and profitable → Breakeven reached, with $1M+ signed for 2025 and revenue projected at $14.6M by 2027
✅ Proven 100x efficiency gain → Traditional BRA takes 18 months, ou SaaS solution provides it in 1 minute
✅ Only contextualizing Small Language Models (SLMs) in biopharma, delivering exhaustiveness + accuracy

💡 Why Invest?
With AI-native scalability, a proven market fit, and a dominant position in a high-barrier market, ArcaScience is set to transform drug development, market access, and regulatory decision-making worldwide. Now is the time to scale our global footprint and accelerate adoption across pharma, CROs, and defense sectors.